27261587|t|Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin - induced diabetic model
27261587|a|Diabetic nephropathy (DN) is a leading cause of end-stage renal disease in the world. Several signaling pathways are involved in the pathogenesis of DN including elevation in level of angiotensin II, formation of advanced glycation end products (AGE), activation of protein kinase c (PKC), and lipid accumulation. These pathways activate one another mutually leading to oxidative stress, increasing expression of transforming growth factor beta-1 (TGF-β 1) and release of interleukins and adhesion molecules, so the aim of this study is to interrupt more than pathogenic pathway to ameliorate the progression of DN. In the present study, white male rats (N=48) were divided into six groups (8 rats each), the first two groups served as normal control and a control vehicle group while the remaining four groups were rendered diabetic by a single intraperitoneal injection of Streptozotocin (STZ) and being left for 4 weeks to develop DN. Thereafter, the rats were divided into DN group, DN group receiving Telmisartan or Sildenafil or Telmisartan Sildenafil combination. After the specified treatment period, urine samples were collected (using metabolic cages) to measure proteinuria, animals were then euthanized, blood and tissue samples were collected for measurement of Blood glucose, BUN, S.Cr, LDL, NO, TGF-β1, IL-1β, AGEPs, and SOD. The combination therapy showed significant decrease in BUN, S.Cr, LDL, TGF-β1, IL-1β, Proteinuria and AGEPs and significant increase in SOD and NO. The findings showed that combination therapy was able to ameliorate DN and that the effects were superior to the single drugs alone.
27261587	0	11	Combination	T103	UMLS:C0013162
27261587	15	26	telmisartan	T103	UMLS:C0248719
27261587	32	42	sildenafil	T103	UMLS:C0529793
27261587	54	65	progression	T038	UMLS:C0242656
27261587	69	89	diabetic nephropathy	T038	UMLS:C0011881
27261587	93	107	streptozotocin	T103	UMLS:C0038432
27261587	118	126	diabetic	T033	UMLS:C0241863
27261587	133	153	Diabetic nephropathy	T038	UMLS:C0011881
27261587	155	157	DN	T038	UMLS:C0011881
27261587	181	204	end-stage renal disease	T038	UMLS:C0022661
27261587	227	245	signaling pathways	T038	UMLS:C0037080
27261587	266	278	pathogenesis	T038	UMLS:C0699748
27261587	282	284	DN	T038	UMLS:C0011881
27261587	295	304	elevation	T082	UMLS:C0702240
27261587	317	331	angiotensin II	T103	UMLS:C0003009
27261587	346	377	advanced glycation end products	T103	UMLS:C0162574
27261587	379	382	AGE	T103	UMLS:C0162574
27261587	385	395	activation	T038	UMLS:C1819041
27261587	399	415	protein kinase c	T103	UMLS:C0033634
27261587	417	420	PKC	T103	UMLS:C0033634
27261587	427	445	lipid accumulation	T033	UMLS:C0333574
27261587	453	461	pathways	T038	UMLS:C0037080
27261587	503	519	oxidative stress	T038	UMLS:C0242606
27261587	532	542	expression	T038	UMLS:C1171362
27261587	546	579	transforming growth factor beta-1	T103	UMLS:C1704256
27261587	581	588	TGF-β 1	T103	UMLS:C1704256
27261587	605	617	interleukins	T103	UMLS:C0021764
27261587	622	640	adhesion molecules	T103	UMLS:C0007578
27261587	693	703	pathogenic	T033	UMLS:C3816499
27261587	730	741	progression	T038	UMLS:C0242656
27261587	745	747	DN	T038	UMLS:C0011881
27261587	764	769	study	T062	UMLS:C0008972
27261587	958	966	diabetic	T033	UMLS:C0241863
27261587	979	1004	intraperitoneal injection	T058	UMLS:C0021493
27261587	1008	1022	Streptozotocin	T103	UMLS:C0038432
27261587	1024	1027	STZ	T103	UMLS:C0038432
27261587	1067	1069	DN	T038	UMLS:C0011881
27261587	1110	1112	DN	T038	UMLS:C0011881
27261587	1120	1122	DN	T038	UMLS:C0011881
27261587	1139	1150	Telmisartan	T103	UMLS:C0248719
27261587	1154	1164	Sildenafil	T103	UMLS:C0529793
27261587	1168	1179	Telmisartan	T103	UMLS:C0248719
27261587	1180	1190	Sildenafil	T103	UMLS:C0529793
27261587	1191	1202	combination	T103	UMLS:C0013162
27261587	1242	1255	urine samples	T031	UMLS:C1610733
27261587	1306	1317	proteinuria	T033	UMLS:C0033687
27261587	1319	1326	animals	T204	UMLS:C0003062
27261587	1349	1354	blood	T031	UMLS:C0178913
27261587	1359	1373	tissue samples	T017	UMLS:C1292533
27261587	1393	1421	measurement of Blood glucose	T058	UMLS:C0392201
27261587	1423	1426	BUN	T058	UMLS:C0005845
27261587	1428	1432	S.Cr	T058	UMLS:C0201976
27261587	1434	1437	LDL	T058	UMLS:C0202117
27261587	1439	1441	NO	T058	UMLS:C3810607
27261587	1443	1449	TGF-β1	T058	UMLS:C3889969
27261587	1451	1456	IL-1β	T058	UMLS:C3815172
27261587	1458	1463	AGEPs	T058	UMLS:C0022885
27261587	1469	1472	SOD	T058	UMLS:C0022885
27261587	1478	1497	combination therapy	T058	UMLS:C0013218
27261587	1529	1532	BUN	T103	UMLS:C0600137
27261587	1534	1538	S.Cr	T103	UMLS:C0010294
27261587	1540	1543	LDL	T103	UMLS:C0023823
27261587	1545	1551	TGF-β1	T103	UMLS:C1704256
27261587	1553	1558	IL-1β	T103	UMLS:C0021753
27261587	1560	1571	Proteinuria	T033	UMLS:C0033687
27261587	1576	1581	AGEPs	T103	UMLS:C0162574
27261587	1610	1613	SOD	T103	UMLS:C0038838
27261587	1618	1620	NO	T103	UMLS:C0028128
27261587	1647	1666	combination therapy	T058	UMLS:C0013218
27261587	1690	1692	DN	T038	UMLS:C0011881
27261587	1742	1747	drugs	T103	UMLS:C0013227